GMT Capital Corp Boosts Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

GMT Capital Corp raised its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 11.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 457,500 shares of the medical equipment provider's stock after acquiring an additional 47,800 shares during the quarter. Lantheus makes up approximately 2.0% of GMT Capital Corp's portfolio, making the stock its 17th biggest position. GMT Capital Corp owned 0.66% of Lantheus worth $40,928,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. lifted its holdings in Lantheus by 40.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock worth $135,025,000 after buying an additional 435,445 shares in the last quarter. Pinebridge Investments L.P. increased its position in shares of Lantheus by 42.7% during the fourth quarter. Pinebridge Investments L.P. now owns 21,748 shares of the medical equipment provider's stock worth $1,946,000 after acquiring an additional 6,507 shares during the period. Stifel Financial Corp raised its stake in shares of Lantheus by 14.3% in the fourth quarter. Stifel Financial Corp now owns 38,497 shares of the medical equipment provider's stock valued at $3,444,000 after acquiring an additional 4,816 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Lantheus by 6.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,178 shares of the medical equipment provider's stock valued at $463,000 after acquiring an additional 309 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky boosted its holdings in Lantheus by 55.2% in the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 33,189 shares of the medical equipment provider's stock valued at $2,969,000 after purchasing an additional 11,798 shares during the period. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Lantheus

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. The trade was a 10.76 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of Lantheus stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares in the company, valued at approximately $11,445,207.20. This trade represents a 8.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 63,109 shares of company stock worth $6,016,046 in the last 90 days. 2.00% of the stock is owned by insiders.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $99.57 on Wednesday. Lantheus Holdings, Inc. has a 12 month low of $62.59 and a 12 month high of $126.89. The firm has a market capitalization of $6.82 billion, a P/E ratio of 16.57 and a beta of 0.20. The company's fifty day moving average price is $96.11 and its 200 day moving average price is $95.36.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to analysts' expectations of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. On average, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on LNTH shares. B. Riley decreased their price objective on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research note on Friday, March 21st. JMP Securities reiterated a "market outperform" rating and issued a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. Finally, Truist Financial boosted their price target on shares of Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, Lantheus has an average rating of "Moderate Buy" and a consensus target price of $129.43.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.